Abstract
The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) curated consensus somatic mutation calls using whole exome sequencing (WES) and whole genome sequencing (WGS), respectively. Here, as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, which aggregated whole genome sequencing data from 2,658 cancers across 38 tumour types, we compare WES and WGS side-by-side from 746 TCGA samples, finding that ~80% of mutations overlap in covered exonic regions. We estimate that low variant allele fraction (VAF < 15%) and clonal heterogeneity contribute up to 68% of private WGS mutations and 71% of private WES mutations. We observe that ~30% of private WGS mutations trace to mutations identified by a single variant caller in WES consensus efforts. WGS captures both ~50% more variation in exonic regions and un-observed mutations in loci with variable GC-content. Together, our analysis highlights technological divergences between two reproducible somatic variant detection efforts.
Introduction
In cancer genomics, researchers typically choose between two paths: Whole Exome Sequencing (WES), which targets the ~2% of the genome that codes for proteins, and Whole Genome Sequencing (WGS), which sequences the entire genome. WES is cost-effective and has been the workhorse of large projects like The Cancer Genome Atlas (TCGA), while WGS is more comprehensive but significantly more expensive. The central question is: How much biological information is lost by choosing one over the other? Previous studies suggested discrepancies, but they were often confounded by different bioinformatics pipelines or small sample sizes. This paper leverages a unique dataset where the same 746 tumor samples were processed by two massive consortia—MC3 (WES-focused) and PCAWG (WGS-focused)—to pinpoint exactly where and why these two "gold standard" approaches diverge.
Methods and Datasets
The researchers performed a retrospective evaluation of mutation calls from 746 TCGA samples across 22 different cancer types. To ensure a fair "apples-to-apples" comparison, the team restricted the search space by limiting WGS data to the specific exonic regions targeted by WES "baits" and employed a reciprocal coverage strategy, only analyzing mutations in regions with sufficient sequencing depth in both technologies.
The study utilized variant calls from two major repositories:
- MC3 (Multi-Center Mutation Calling in Multiple Cancers): The consensus WES variant calls for TCGA.
- PCAWG (Pan-Cancer Analysis of Whole Genomes): The consensus WGS variant calls from the ICGC/TCGA consortium.
To facilitate comparison, the researchers developed MAFit, a web-based graphical interface that allows users to interactively compare and filter these merged mutation sets. They also used random forest regression and binomial models to determine if "private" mutations (those found by only one method) were due to sequencing noise, low Variant Allele Fraction (VAF), or biological factors like subclonal heterogeneity.
Key Insights: The Drivers of Discrepancy
Overall, the two platforms showed 76.7% concordance, with over 70% of samples showing an overlap greater than 80%. However, several key factors drive the remaining discrepancies:
The VAF Sensitivity Gap
The single biggest driver of discrepancy is the Variant Allele Fraction (VAF). Mutations with a VAF < 15% accounted for roughly 70% of the "private" mutations. At these low frequencies, the stochastic nature of sequencing means one platform may simply miss a mutation that the other catches.
GC-Content and Capture Bias
WES relies on hybrid capture (using "baits" to grab DNA), a process notoriously biased by GC-content. The study found that WGS provides much more uniform coverage, catching critical driver mutations (such as VHL in kidney cancer) in GC-rich regions that WES consistently overlooked.
The "Dark Matter" of Exons
Even within "exonic" regions, WGS captured ~50% more variation. This is because WGS naturally sequences the flanking regions—such as 5’ and 3’ Untranslated Regions (UTRs)—which are often poorly covered or entirely ignored by standard WES exome kits. The study highlighted recurrent mutations in the 3’UTRs of genes like PGR and ERBB4 that were only visible via WGS and correlated with changes in gene expression.
Conclusion
Interestingly, the specific bioinformatics "callers" used were less of a factor than the underlying sequencing technology. When both platforms had high coverage and the mutation frequency was high, they almost always agreed. WGS identified 424 mutations in known cancer genes that were missed by WES, primarily due to low VAF or poor capture bait efficiency.
While the authors acknowledge that spatial heterogeneity (different mutations in different parts of the same tumor) remains a challenge, they conclude that the discrepancies are primarily technological. As sequencing costs fall, a transition toward WGS is expected; in the interim, tools like MAFit are essential for reconciling these two massive datasets and understanding the technological divergences that define modern cancer genomics.
Summary updated